{"product_id":"memorial-sloan-kettering-cancer-center-state-of-the-art-in-benign-hematology-hemostasis-and-thrombosis-2025","title":"Memorial Sloan Kettering Cancer Center State-of-the-Art in Benign Hematology, Hemostasis, and Thrombosis 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: general medicine, hematology\/oncology, fellows, hospitalists, nocturnists, emergency medicine providers\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSpecialties – Emergency Medicine, Hematology, Hematopathology, Hospitalist, Immunotherapy, Internal Medicine, Interventional Radiology, Leukemia, Nurse Practitioner, Oncology and Hematology, Physician Assistant, Pulmonary Medicine, Transfusion Medicine\u003c\/p\u003e\n\u003cp\u003eOverview\u003c\/p\u003e\n\u003cp\u003eThis one-day symposium will provide a state-of-the-art update in benign hematology, with a particular focus on emerging therapeutic strategies. The program will feature in-depth presentations by expert faculty, with dedicated time for interactive discussion and Q\u0026amp;A.\u003c\/p\u003e\n\u003ch3\u003eNow in its 10th year, the 2025 program will focus on:\u003c\/h3\u003e\n\u003cp\u003eComplex management scenarios in hemostasis and thrombosis, including stroke in cancer, cardiac thrombosis, and thrombotic risk in acute lymphoblastic leukemia (ALL)\u003c\/p\u003e\n\u003cp\u003eAdvances in management of hemolytic anemias, with a focus on the therapeutic management of hereditary anemia, paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease, and other complement-mediated hemolytic disorders\u003c\/p\u003e\n\u003cp\u003eHematologic complications related to cellular therapies and immunotherapies\u003c\/p\u003e\n\u003cp\u003eNovel treatment approaches, including factor XI inhibitors and anticomplement agents, and the unique challenges associated with their use\u003c\/p\u003e\n\u003cp\u003eThe target audience for this symposium includes general medicine, hematology\/oncology, fellows, hospitalists, nocturnists, emergency medicine providers, advanced practice providers and other healthcare professionals who manage and treat thrombotic and bleeding disorders. Please note that this symposium will be offered exclusively in person; a virtual attendance option will not be available.\u003c\/p\u003e\n\u003cp\u003eFollowing the symposium, registrants will receive access to an online syllabus featuring select PDF slides from faculty presentations and recorded session videos.\u003c\/p\u003e\n\u003cp\u003eObjectives\u003c\/p\u003e\n\u003ch3\u003eAt the conclusion of this symposium, attendees will be able to:\u003c\/h3\u003e\n\u003cp\u003eDiscuss current updates in the management of challenging benign hematologic conditions, with a focus on emerging therapeutics\u003c\/p\u003e\n\u003cp\u003eAnalyze current data and discuss emerging FXI inhibitors\u003c\/p\u003e\n\u003cp\u003eDescribe anticomplement therapies\u003c\/p\u003e\n\u003cp\u003eRecognize the challenges in diagnosis and management of hematologic complications of immunotherapy\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSunday, October 26, 2025\u003c\/p\u003e\n\u003cp\u003eEmerging Data on Factor XI Inhibitors\u003c\/p\u003e\n\u003cp\u003eJeffrey Zwicker, MD\u003c\/p\u003e\n\u003cp\u003eCryptogenic Stroke and Cancer\u003c\/p\u003e\n\u003cp\u003eBabak Navi, MD\u003c\/p\u003e\n\u003cp\u003eBenefits of Extended Post-op Thromboprophylaxis in the Era of Robotic Surgery\u003c\/p\u003e\n\u003cp\u003eMarc Carrier, MD\u003c\/p\u003e\n\u003cp\u003eThrombotic Risk in Acute Lymphoblastic Leukemia\u003c\/p\u003e\n\u003cp\u003eAvi Leader, MD\u003c\/p\u003e\n\u003cp\u003eInherited Hemolytic Anemias: Scientific Advances in Therapeutics\u003c\/p\u003e\n\u003cp\u003eMohandas Narla, DSc\u003c\/p\u003e\n\u003cp\u003eAnticomplement Therapy for Paroxysmal Nocturnal Hemoglobinuria\u003c\/p\u003e\n\u003cp\u003edavid araten, MD\u003c\/p\u003e\n\u003cp\u003eManagement of Cold Agglutinin Disease\u003c\/p\u003e\n\u003cp\u003eRekha Parameswaran, MD\u003c\/p\u003e\n\u003cp\u003eHLH-like Toxicities Secondary to Cancer Immunotherapy\u003c\/p\u003e\n\u003cp\u003eWilliam Johnson, DO\u003c\/p\u003e\n\u003cp\u003eThrombosis Related to Immune Therapy\u003c\/p\u003e\n\u003cp\u003eJodi Mones, MD\u003c\/p\u003e\n\u003cp\u003eUpdates in Immune Thrombocytopenia\u003c\/p\u003e\n\u003cp\u003eCy R Wilkins, MD\u003c\/p\u003e\n\u003cp\u003eTransplant-Associated Thrombotic Microangiopathy\u003c\/p\u003e\n\u003cp\u003eMohammad Alhomoud, MBBS\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405798887620,"sku":null,"price":52.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Memorial-Sloan-Kettering-Cancer-Center-State-of-the-Art-in-Benign-Hematology-Hemostasis-and-Thrombosis-2025.jpg?v=1784216307","url":"https:\/\/medicalcoursespro.com\/products\/memorial-sloan-kettering-cancer-center-state-of-the-art-in-benign-hematology-hemostasis-and-thrombosis-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}